Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,777.20
(
-0.08%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.42
(
3.60%
)
Bitcoin
70,427.84
(
-1.14%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: rkrw post# 86175

Monday, 11/16/2009 1:59:03 AM

Monday, November 16, 2009 1:59:03 AM

Post# of 257257
Anyone following the Introgen story closely would say the same thing. They actually claimed in SEC filings they had a SPA on their Advexin trials. This was false, as I got them to admit on a conference call (the last call where they took my questions).

One more instance of the SEC and NASD asleep at the switch.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now